Ethanolamines

Publication Title: 
The Journal of Infectious Diseases

New antimalarial drugs are urgently needed. The use of short courses of the new antimalarial drug artemether as monotherapy has been limited by secondary malaria episodes following parasite clearance. Therefore, a new antimalarial drug, CGP 56697, has been developed, which combines artemether with a longer-acting antimalarial agent, benflumetol. A safety trial was undertaken in 60 Gambian children 1-6 years old with uncomplicated Plasmodium falciparum malaria. All children treated with CGP 56697 cleared their parasites 72 h after the start of treatment.

Author(s): 
von Seidlein, L.
Jaffar, S.
Pinder, M.
Haywood, M.
Snounou, G.
Gemperli, B.
Gathmann, I.
Royce, C.
Greenwood, B.
Publication Title: 
Antimicrobial Agents and Chemotherapy

An open, randomized comparison of artemether-benflumetol (CGP 56 697; Novartis) with artesunate-mefloquine was conducted in 617 patients with acute uncomplicated multidrug-resistant falciparum malaria on the western border of Thailand. Both treatments rapidly and reliably cleared fever and parasitemia, and there was no significant difference in the initial therapeutic response parameters. Parasite genotyping was used to distinguish recrudescences from new infections.

Author(s): 
van Vugt, M.
Brockman, A.
Gemperli, B.
Luxemburger, C.
Gathmann, I.
Royce, C.
Slight, T.
Looareesuwan, S.
White, N. J.
Nosten, F.
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

We report here the results of a randomized double blind trial comparing coartemether (CGP56697), a combination of artemether and benflumetol, with pyrimethamine/sulfadoxine (P/S). Two hundred eighty-seven children 1-5 years of age with uncomplicated falciparum malaria were enrolled at two centers in The Gambia between July 1996 and December 1996. Following treatment, children were visited at home every 24 hr until a blood film free of asexual parasites was obtained. Genotyping of parasites was used to distinguish recrudescence from new infections.

Author(s): 
von Seidlein, L.
Bojang, K.
Jones, P.
Jaffar, S.
Pinder, M.
Obaro, S.
Doherty, T.
Haywood, M.
Snounou, G.
Gemperli, B.
Gathmann, I.
Royce, C.
McAdam, K.
Greenwood, B.
Publication Title: 
Tropical medicine & international health: TM & IH

OBJECTIVE: To test the efficacy of a new compound drug (CGP 56697) against acute, uncomplicated falciparum malaria. METHOD: Reappearing parasites were analysed by PCR-RFLP within a randomized controlled trial. 130 patients received chloroquine and 130 patients were treated with CGP 56697. Samples from 96 patients with parasitological failure were tested by PCR-RFLP for MSP2 of Plasmodium falciparum. Seven days after treatment 32 patients of the chloroquine control group with reappearing parasites were tested by PCR and one infection was unequivocally determined as a new infection.

Author(s): 
Irion, A.
Felger, I.
Abdulla, S.
Smith, T.
Mull, R.
Tanner, M.
Hatz, C.
Beck, H. P.
Publication Title: 
Tropical medicine & international health: TM & IH

A randomized, open trial involving 260 Tanzanian children, aged 1-5 years, with acute Plasmodium falciparum malaria was conducted to evaluate the efficacy of the combination antimalarial CGP 56697 (artemether and benflumetol), and to compare it with chloroquine, the standard drug used for malaria treatment in the Kilombero area. Children who had received rescue medication within the first 48 h or had a negative slide at the same time were excluded. Seven-day parasitological cure rates were 94% (95% CI 88-97.5) for CGP 56697 and 35.4% (95% CI 25.9-45.8) for chloroquine.

Author(s): 
Hatz, C.
Abdulla, S.
Mull, R.
Schellenberg, D.
Gathmann, I.
Kibatala, P.
Beck, H. P.
Tanner, M.
Royce, C.
Publication Title: 
British Journal of Clinical Pharmacology

AIMS: To investigate the pharmacokinetic and pharmacodynamic properties of artemether and benflumetol in a fixed combination tablet (CGP 56697) and to offer an explanation for the lower than expected cure rate in a Thai clinical trial. METHODS: Two hundred and sixty patients were enrolled into a randomized, double-blind, parallel group, dose-finding trial. CGP 56697 was given orally, either as: A, 4 x 4 tablets over 48 h; B, 4 x 2 tablets over 48 h or C, 3 x 4 tablets over 24 h. Each tablet contained artemether 20 mg amd benflumetol 120 mg.

Author(s): 
Ezzet, F.
Mull, R.
Karbwang, J.
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

CGP 56697, a new oral fixed combination of artemether and benflumetol, was tested in a double-blinded, randomized trial in 252 adult patients treated either with CGP 56697 (4 x 4 tablets each containing 20 mg of artemether and 120 mg of benflumetol, given at 0, 8, 24, and 48 hr), or with mefloquine (three tablets of 250 mg at initial diagnosis, followed by two tablets of 250 mg at 8 hr). Baseline data of the two groups were comparable. The 28-day cure rate with CGP 56697 was lower than with mefloquine (69.3% versus 82.4%; P = 0.002).

Author(s): 
Looareesuwan, S.
Wilairatana, P.
Chokejindachai, W.
Chalermrut, K.
Wernsdorfer, W.
Gemperli, B.
Gathmann, I.
Royce, C.
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

The new oral fixed combination artemether-lumefantrine (CGP 56697) has proved to be an effective and well-tolerated treatment of multi-drug resistant Plasmodium falciparum malaria, although cure rates using the four-dose regimen have been lower than with the currently recommended alternative of artesunate-mefloquine.

Author(s): 
Vugt, M. V.
Wilairatana, P.
Gemperli, B.
Gathmann, I.
Phaipun, L.
Brockman, A.
Luxemburger, C.
White, N. J.
Nosten, F.
Looareesuwan, S.
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

Using a continuous in vitro culture system, the sensitivity of Plasmodium falciparum to artemether and a new antimalarial drug, benflumetol (lumefantrine), alone and in combination, was investigated with a multiresistant strain (T-996) from Thailand and a chloroquine-resistant strain (LS-21) from India.

Author(s): 
Hassan Alin, M.
Bjorkman, A.
Wernsdorfer, W. H.
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.

Author(s): 
van Vugt, M.
Ezzet, F.
Nosten, F.
Gathmann, I.
Wilairatana, P.
Looareesuwan, S.
White, N. J.

Pages

Subscribe to RSS - Ethanolamines